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Key points 
 Nephrogenic diabetes insipidus (NDI) is caused by inability of the kidneys to 
concentrate urine by reabsorption of water in the collecting duct 
 NDI can be inherited (X-linked or autosomal) or acquired, most commonly as 
a result of lithium treatment 
 Management of primary forms of NDI focuses on dietary modification to 
reduce osmotic load and pharmacological treatment with prostaglandin 
synthesis inhibitors and thiazide diuretics 
 With appropriate treatment, complications of NDI, such as failure to thrive 
and mental retardation resulting from repeated hypernatraemic dehydration, 
can be avoided 
 New treatment approaches for congenital NDI have been tested in animal 
models, but efficacy in patients has not yet been confirmed 
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Abstract 
Healthy kidneys maintain fluid and electrolyte homoeostasis by adjusting urine 
volume and composition according to physiological needs. The final urine 
composition is determined in the last tubular segment: the collecting duct. Water 
permeability in the collecting duct is regulated by arginine vasopressin (AVP). 
Secretion of AVP from the neurohypophysis is regulated by a complex signalling 
network that involves osmosensors, barosensors and volume sensors. AVP 
facilitates aquaporin (AQP)-mediated water reabsorption via activation of the 
vasopressin V2 receptor (AVPR2) in the collecting duct, thus enabling 
concentration of urine. In nephrogenic diabetes insipidus (NDI), inability of the 
kidneys to respond to AVP results in functional AQP deficiency. Consequently, 
affected patients have constant diuresis, resulting in large volumes of dilute 
urine. Primary forms of NDI result from mutations in the genes that encode the 
key proteins AVPR2 and AQP2, whereas secondary forms are associated with 
biochemical abnormalities, obstructive uropathy or the use of certain 
medications, particularly lithium. Treatment of the disease is informed by 
identification of the underlying cause. Here we review the clinical and diagnostic 
aspects of NDI, the various aetiologies, current treatment options and potential 
future developments. 
[H1] Introduction 
Nephrogenic diabetes insipidus (NDI) results from failure of the kidneys to 
concentrate urine. Patients with this disease typically produce around 12 l of 
urine per day. Assuming a bladder volume of 500 ml, this volume of urine will 
necessitate voiding approximately once per hour throughout the day and night. 
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Moreover urinary fluid losses need to be replenished by constant fluid intake. 
The disease has a substantial impact on quality of life as sleep is frequently 
interrupted and patients must plan their daily activities with logistics for 
frequent voiding and access to drinking water. 
 Primary and secondary forms of NDI exist. Paediatricians typically see 
patients with primary inherited forms of the disease, mostly boys presenting in 
the first year of life with failure-to-thrive and vomiting. By contrast, in adults 
acquired NDI is much more common than primary NDI. Medical treatment can 
ameliorate the symptoms of NDI and as understanding of the underlying 
pathophysiology improves, new potential treatment options arise. In this Review 
we consider the clinical, diagnostic and therapeutic aspects of NDI in the context 
of the physiology of renal water handling to enable a molecular understanding of 
the disease. We also discuss recent insights into the regulation of water 
permeability and their consequences with respect to diagnosis and new 
treatment options. 
[H1] Physiology of urine concentration 
Healthy adult kidneys produce approximately 180 l of primary glomerular 
filtrate per day.1 The vast majority of this filtrate is reabsorbed in the proximal 
tubule, which is freely permeable to water owing to the constitutive expression 
of aquaporin (AQP)-1 water channels.2 As solutes are reabsorbed in the proximal 
tubule, water follows passively along the osmotic gradient. The remaining urine 
is thus still isotonic when it enters the loop of Henle, the key segment for 
counter-current concentration (Figure 1). Urine concentration begins in the thin 
descending limb (TDL). Mechanisms of concentration include AQP1-mediated 
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exit of water into the medullary interstitium.3 However, data from several rodent 
models show that Aqp1 expression is mainly restricted to the first 60% of the 
TDL rather than to the deeper papillary parts in which the steepest part of the 
osmotic gradient is generated.4 Concentration of the tubular fluid in these 
innermost parts of the TDL might occur via passive sodium influx,5 but no 
substantial sodium permeability has been observed.6 Thus, the exact mechanism 
of urinary concentration in the innermost part of the medulla remains to be 
elucidated. 
 
Urine subsequently enters the thick ascending limb (TAL, also known as the 
diluting segment), which is impermeable to water but actively removes sodium 
chloride via the co-transporter solute carrier family 12 member 1 (SLC12A1,  
also known as NKCC2), thereby diluting the urine.7 The accumulation of solutes 
in the interstitium generates the driving force for the removal of water from the 
TDL (in long-looped nephrons) and the entry of sodium chloride (in short-looped 
nephrons), completing the counter-current multiplier. 
 
Further removal of sodium chloride occurs in the distal convoluted tubule via 
SLC12A3 (also known as NCC). At entry into the arginine vasopressin (AVP)-
sensitive connecting tubules and collecting ducts, urine osmolality is typically 
around 50–100 mOsm/kg. The final osmolality of the urine is solely dependent 
on the availability of water channels. If these channels are present, water exits 
the tubule following the interstitial concentration gradient and the urine is 
concentrated. If no water channels are present, dilute urine will be excreted. 
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[H1] Vasopressin-regulated water permeability 
Vasopressin secreted by hypothalamic neurons in response to changes in soma 
volume (Figure 2) is the key regulator of the water permeability of the collecting 
ducts. The key cell type that mediates this regulated water permeability is the 
principal cell, which constitutively expresses AQP3 and AQP4 on the basolateral 
side.2 The water permeability of the apical membranes of the principal cell is 
determined by the availability of AQP2 water channels. In the absence of AVP 
signalling, these channels are located in intracellular vesicles and no apical water 
permeability exists.8  Binding of AVP to the vasopressin V2 receptor (AVPR2) 
initiates a signalling cascade that ultimately leads to the insertion of AQP2 
channels into the apical membrane(Figure 3). AVPR2 is a G-protein-coupled 
receptor and binding of AVP leads to the release of stimulatory G-protein, which 
in turn activates the neighbouring adenylyl cyclase.9 The resulting increase in 
levels of cAMP activates protein kinase A (PKA). 
 
The cytoplasmic carboxy-terminal tail of AQP2 has five canonical PKA-
phosphorylation sites: Thr244, Ser256, Ser261, Ser264 and Thr269 (Ser269 in 
mice).10 Upon administration of the vasopressin analogue 1-desamino-8-D-
arginine vasopressin (DDAVP), phosphorylation of AQP2 at Ser256, Ser264 and 
Ser269 is abundantly increased, whereas phosphorylation at Ser261 is 
decreased;10 specific phosphorylation of these residues might serve distinct 
physiological roles. In a mammalian cell line (LLC-PK1) transiently transfected 
with AQP2, phosphorylation at Ser256 was essential for trafficking of the water 
channel to the plasma membrane,11 whereas in Xenopus oocytes, 
phosphorylation of at least three subunits of the AQP2 tetramer at Ser256 was 
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required for redistribution from storage vesicles to the apical plasma 
membrane.12 The critical role of Ser256 in AQP2 function was confirmed by the 
identification of mutations that impair phosphorylation at this site in patients 
with NDI.13, 14 In vitro studies demonstrated the failure of such mutants to reach 
the apical membrane.13, 14  
 
AVP also induces phosphorylation of AQP2 at Ser269, but this action is delayed 
and requires prior phosphorylation at Ser265.15 Phosphorylation at Ser269 
might increase retention of AQP2 at the apical plasma membrane and 
interactions of AQP2 with proteins participating in the endocytic machinery.16 By 
contrast, AQP2 phosphorylated at Ser261 is found mainly in intracellular 
vesicles; phosphorylation at this site is thought to stabilize ubiquitination of 
AQP217 at Lys270.18 Ubiquitination might, therefore, mediate the endocytosis of 
AQP2 from the plasma membrane in the absence of AVP stimulation. This 
mechanism leads to a limited tenure of AQP2 in the apical membrane of principal 
cells; endocytosis of this water channel enables the cells to return to their water-
impermeable state. The role of AQP2 phosphorylation at Thr244 is unknown. 
 
The actions of cAMP might not only be mediated via the classical PKA/cAMP-
dependent protein kinase pathway, but also by guanine nucleotide-exchange 
factors such as exchange protein directly activated by cAMP (Epac).19  Like PKA, 
Epac contains an evolutionally conserved cAMP-binding domain that senses 
intracellular cAMP levels and acts as a molecular switch to control diverse 
biological functions.20  Epac might be involved in the long-term regulation of 
AQP2 abundance, whereas PKA has independent short-term effects.21 
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In addition to an acute role in AQP2 localization, AVP-mediated increases in 
cAMP promote AQP2 expression via PKA-mediated phosphorylation of the cAMP 
responsive element binding protein, which subsequently stimulates 
transcription from the AQP2 promoter.22-24 The change in localization of AQP2 
occurs within minutes, whereas the increase in transcription requires hours to 
take effect.25,26 
 [H1] Congenital NDI 
In 1992 the AVPR2 gene that encodes the AVP2 receptor was cloned and 
mutations in this gene were identified in patients with X-linked NDI (Figure 4).27-
30 The AQP2 gene was cloned in 199331, 32 and in 1994 mutations in AQP2 were 
found to underlie autosomal recessive NDI.33 The discovery of these two key 
genes—AVPR2 and AQP2—has enabled genetic testing of affected patients. 
Mutations in either of these genes are identified in almost all patients with a 
clear clinical phenotype of congenital NDI.34, 35 
[H2] AVPR2 mutations 
Approximately 90% of patients with inherited NDI have a mutation in AVPR2.36, 
37  As this gene is located on the X-chromosome, AVPR2 mutations have an X-
linked pattern of inheritance; consequently the majority of patients with NDI are 
male. Occasionally, female patients with NDI due to AVPR2 mutations have been 
described.34, 35, 38-41 In one study, 16 of 64 (25%) female carriers of AVPR2 
mutations showed polyuric symptoms and four of these patients (6%) were 
diagnosed with complete NDI rather than the milder partial NDI phenotype 
described below.34 Skewed X-inactivation is thought to cause symptoms in some 
female carriers of AVPR2 mutations, although these symptoms do not necessarily 
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correlate with the X-inactivation patterns observed in leukocytes.42 Presumably, 
X-inactivation patterns can differ between tissues, so the pattern in leukocytes 
might not reflect that in the kidney. In our experience at Great Ormond Street 
Hospital, London, UK, two female relatives in 20 families with AVPR2 mutations 
have been diagnosed with complete NDI (unpublished data). One of these 
women was the index case in her family, but not all female carriers have been 
systematically investigated. Partial NDI symptoms were observed in two other 
female carriers in one family.43 
 
A few AVPR2 mutations have been identified recurrently owing to a founder 
effect. For example, the Hopewell mutation (Trp71X)—derived from an Ulster 
Scot immigrant who arrived in Halifax, Canada on the ship Hopewell in 1761—
has been identified in >40 North American patients.44, 45 Another recurrent 
mutation is the Cannon mutation (Leu312X), which is named after a large 
pedigree with ≥38 affected patients in Utah.45 Most patients, however, have 
individual mutations; to date >250 different AVPR2 mutation have been 
described in >300 families (46 and our unpublished data). Interestingly, most of 
these mutations are missense and, when assessed in vitro, seem to encode 
functional but misfolded receptors, which are retained and degraded in the 
endoplasmic reticulum (ER).47 
[H3] AQP2 mutations 
Approximately 10% of cases of congenital NDI are due to loss-of-function 
mutations in the AQP2 gene located on chromosome 12.45,34, 48 These mutations 
are typically inherited in an autosomal recessive fashion, although a few 
mutations have been described to cause autosomal dominant disease.13, 49-51 
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AQP2 is a homotetramer; four subunits assemble to form the water channel. 
Dominant mutations typically affect amino acids in the C-terminus, leading to 
aberrant trafficking; mutant AQP2 subunits are able to oligomerize with wild-
type protein to form tetramers, but exert a dominant-negative effect on 
trafficking of these assembled tetramers.52 Interestingly, specific mutations 
direct AQP2 trafficking to distinct cellular compartments, such as the Golgi 
complex,13 late endosomes and lysosomes49 or the basolateral membrane.51, 53 
These findings have provided insights into the intracellular trafficking motifs of 
AQP2. 
[H2] Epidemiology  
Few population-based data on the incidence of congenital NDI exist, but 
estimates can be made. In 2000 we assumed that we had complete 
ascertainment of all the patients with AVPR2 mutations who were born in the 
province of Quebec, Canada between 1988 and 1997.35 Indeed, in the subsequent 
18 years, no patients with AVPR2 mutations born in the province during this 
period have emerged. Based on these data, we estimated the incidence of X-
linked NDI in the general population of Quebec to be four in 454,629 or 
approximately 8.8 per million (SD 4.4 per million) male live births. This estimate 
might be representative of the general world population. However, owing to 
chance population genetic events, such as a founder effect, the incidence of NDI 
is elevated in certain regions. For example, in the Canadian maritime provinces 
of Nova Scotia and New Brunswick, we estimate the incidence of the Hopewell 
mutation to be 58 per million male live births.35 A higher incidence of NDI is also 
found in Utah due to the prevalence of the Cannon mutation.44 
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Based on the families referred to us for genetic testing, we estimate that the 
incidence of NDI secondary to AQP2 mutations is five to ten times lower than 
that of NDI secondary to AVPR2 mutations. The incidence of this type of 
congenital NDI might, however, be increased in populations with a high degree of 
consanguinity; we have found an over-representation of the Val71Met AQP2 
allele in patients of Pakistani descent.54 
[H1] Secondary inherited forms of NDI 
In addition to primary forms of congenital NDI a few cases of secondary 
inherited NDI have been reported.55, 56 These patients have Mendelian diseases 
that affect tubular function with NDI as a secondary complication. In some such 
patients the NDI symptoms dominate the clinical picture, leading to an initial 
misdiagnosis, with the true underlying cause of disease subsequently 
identified.55, 57 Most of the primary diseases associated with secondary NDI, such 
as Bartter syndrome and apparent mineralocorticoid excess, are associated with 
hypokalaemia and hypercalciuria. These associations might provide clues to the 
aetiology of NDI, as both hypokalaemia and hypercalciuria are associated with 
decreased AQP2 expression.58, 59 Hypercalciuria has been suggested to cause a 
urinary concentration defect mediated by the calcium-sensing receptor, which is 
expressed on the luminal side of collecting duct cells and is thought to affect 
AQP2 trafficking by altering cAMP levels.60, 61 
[H1] Acquired NDI 
In adult nephrology practice the majority of patients who present with NDI have 
acquired this disease, with lithium treatment being the predominant cause.62-64 
Reports of NDI among patients treated with lithium vary widely but the 
incidence of this adverse effect has been reported to be as high as 85%.63, 65 As 
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0.25–0.77% of the general population aged >65 years are prescribed lithium, it is 
not surprising that lithium-induced NDI is fairly commonly.66, 67 Indications for 
lithium treatment include bipolar disorder, schizoaffective disorder, depression, 
alcoholism and cluster headaches.64 Cessation of lithium therapy can resolve the 
symptoms of NDI, but this approach is not an option in most cases because the 
beneficial effects of the drug on the psychiatric disorder outweighs the negative 
impact of the polyuric complications on quality of life. 
 
In rats, chronic lithium administration (>4 weeks) led to epithelial remodelling 
in the collecting duct and a dramatic reduction in the number of principal cells.68 
Moreover, in the mouse collecting duct cell line mpkCCD, lithium exposure 
decreased Aqp2 abundance independent of cAMP levels.69 Consistent with these 
data, decreased urinary excretion of AQP2 has been observed in patients with 
lithium-induced NDI.70 The exact mechanism of lithium toxicity on the principal 
cell remains to be elucidated, but robust data suggest that lithium exerts its 
effect after entering the cell through epithelial sodium channels (ENaCs), which 
have a high permeability for lithium.10 Consequently, treatment with ENaC 
blockers, such as amiloride, can increase urine osmolality and ameliorate 
polyuria in lithium-induced NDI.71-73  
 
Other acquired causes of typically transient NDI include hypercalcaemia, 
hypercalciuria and obstructive uropathy. In patients with obstructive uropathy, 
NDI is thought to result from direct suppression of AQP2 expression, which 
might be mediated by hydrostatic pressure. Animal studies have shown 
decreased Aqp2 expression in the setting of bilateral ureteric obstruction,74 
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whereas in unilateral obstruction a marked decrease in Aqp2 is seen only in the 
obstructed kidney.75 This down-regulation of Aqp2 persists up to 30 days after 
release of obstruction, perhaps explaining the diuresis often observed after 
release of severe obstruction in patients.9 
[H1] Initial presentation 
Most patients with congenital NDI present with failure to thrive during the first 
few months of life, whereas those with acquired NDI typically present later in life 
with polyuria and or polydipsia. In patients with congenital NDI the antenatal 
history is typically normal with no polyhydramnios, which helps to distinguish 
NDI from other polyuric disorders, such as Bartter syndrome. Parents often 
report that the baby sucks vigorously but vomits shortly afterwards. This 
vomiting is thought to occur because intake of large fluid volumes causes gastro-
oesophageal reflux. 
 
NDI is a rare disease so does not feature prominently on the diagnostic radar of 
frontline medical staff. Families seeking medical attention for their yet 
undiagnosed baby might, therefore, be sent home without further investigations 
because the attending professionals are falsely reassured by the large urine 
output. Laboratory investigations in such instances would show the typical 
picture of hypernatraemia with inappropriately dilute urine, the biochemical 
“fingerprint” of diabetes insipidus. If blood tests are obtained and 
hypernatraemia is noted without consideration of a urinary concentration 
defect, inappropriate treatment with 0.9% saline might be instigated because of 
concerns regarding too rapid correction of the hypernatraemia. Unfortunately, 
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given the imbalance between the sodium concentration of the administered fluid 
(154 mmol/l) and the urine (usually <10 mmol/l), this approach will result in 
even higher plasma sodium concentrations. 
[H1] Diagnosis 
In patients who present with hypernatraemic dehydration and dilute urine, a 
DDAVP test can help to distinguish between cranial diabetes insipidus (which is 
normally the result of disease of the hypothalamus or surrounding tissues) and 
NDI. In patients with suspected diabetes insipidus who present with polyuria 
and normal plasma biochemistries, a water deprivation test might first be 
performed to challenge urinary concentration. 
[H2] DDAVP test 
As DDAVP has high specificity for AVPR2 it can be used to assess the renal 
response whilst avoiding AVPR1-mediated vasoconstriction. DDAVP is available 
in formulations suitable for oral, intranasal, subcutaneous or intravenous (IV) 
administration. After DDAVP administration a urine osmolality >800 mOsm/kg 
is usually considered normal and excludes a diagnosis of NDI, whereas a urine 
osmolality below plasma osmolality indicates AQP2 deficiency and is consistent 
with the diagnosis. Care needs to be taken in the interpretation of intermediate 
results, especially in infants, as full urinary concentrating ability develops during 
the first year of life.76 Other causes for submaximal values include interstitial 
renal disease, use of loop diuretics, partial NDI, washout of the interstitial 
medullary concentration gradient or technical failure of the test, for example as a 
result of incomplete DDAVP absorption. 
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Various protocols for the DDAVP test exist, but we prefer to use IV 
administration to enable the most reliable absorption of the polypeptide.77 The 
DDAVP dose (0.3 mcg/kg) used in this test is the same as that used to boost 
factor VIII concentration in patients with mild haemophilia or von Willebrand 
disease.78, 79 The key risk of the test is the development of hyponatraemia in 
patients who respond to DDAVP and keep drinking. The physiological 
suppression of thirst from reduced plasma osmolality prevents this complication 
in the vast majority of responders, but patients with habitual polydipsia and 
babies who keep receiving feeds from their carer are at risk. Strict observation of 
fluid balance is required to prevent this potentially serious complication and 
patients should only be allowed to receive a fluid volume equivalent to their 
ongoing losses. 
 
A key advantage of IV administration is the short half-life of DDAVP in blood, 
which necessitates an observation time of only 2 h, thus minimizing the burden 
of the test. Other advantages include a low risk of test failure owing to 
incomplete absorption and the ability to distinguish between X-linked and 
autosomal-recessive forms of NDI, as AVPR2 mediates haemodynamic and 
coagulation factor changes in response to high-dose DDAVP.77 This response is 
abrogated in patients with defective AVPR2 function, yet retained in those with 
mutations in AQP2. The low plasma levels of DDAVP achieved with other forms 
of administration make detection of these subtle changes virtually impossible. 
[H1] Spectrum of clinical disease  
[H2] Mental impairment 
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As with most inherited diseases a wide spectrum of severity of clinical disease is 
observed in NDI. The most severe consequences are seen in patients who have 
not received adequate treatment and have experienced repeated episodes of 
hypernatraemic dehydration, leading to brain damage and impaired mental 
development.39, 80, 81 In some such patients, intracranial calcifications can be 
observed. These calcifications are thought to result from endothelial cell necrosis 
during severe dehydration and thus might represent a radiological correlate to 
brain damage from recurrent hyperosmolar stress associated with 
hypernatraemic dehydration.82 
 
Fortunately, cases of severe mental impairment in patients with NDI are now 
virtually non-existent in countries where modern health care is available. 
Nevertheless, impaired school performance and behavioural abnormalities are 
often reported among patients with NDI. In a Dutch study, 8 of 17 participants 
were diagnosed with attention deficit hyperactivity disorder.83 This diagnosis 
might be partly related to the constant craving for water and need to void. Some 
data, however, suggest that behavioural abnormalities might be an intrinsic 
aspect of the disease. Vasopressin (and oxytocin) act as neurotransmitters that 
modulate the autonomic fear response84 and vasopressin has been described to 
enhance aggressiveness, anxiety and stress levels in an animal model.85 Raised 
vasopressin levels might also potentially affect long-term behaviour in patients 
with NDI. 
[H2] Flow uropathy 
Dilatation of the urinary tract is a recurrently noted complication of NDI and 
patients with poor voiding habits are especially at risk.39, 86, 87 In those with 
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hydronephrosis, anatomic causes of obstruction should also be considered. Such 
obstructions are potentially remediable and even minor impediments to urine 
flow can cause severe dilatation in this polyuric disorder.88 Obstructive 
nephropathy can be seen in cranial diabetes insipidus and NDI, and if untreated 
can lead to obstructive end-stage renal disease. 
[H2] Partial NDI 
Some patients with congenital NDI have a mild phenotype; they present after 
infancy with normal development, often for the assessment of polyuria or 
enuresis, and typically show intermediate urine osmolality after DDAVP 
administration (greater than plasma osmolality but <800 mosm/kg). Patients 
with partial NDI typically carry mutations that result in partial function of either 
AVPR2 43, 89 or AQP2.90, 91 The first mutation to be associated with partial NDI 
was the Asp85Asn mutation in AVPR2.89 Interestingly, another missense 
mutation, Val88Met, has been associated with partial NDI in some patients and 
complete NDI in others.43, 92, 93 The underlying disease mechanism in patients 
with these missense mutations is ER retention of the mutant protein, but degree 
to which the mutant protein can escape from this retention and traffic to the cell 
membrane seems to differ between individual patients. 
[H1] Treatment 
Current treatment approaches for congenital NDI focus on amelioration of the 
symptoms rather than curing the disease. If possible, treatment of acquired NDI 
should   target the underlying cause, such as relief of urinary obstruction or 
amiloride therapy in lithium-associated NDI.73 If such approaches are not 
possible, treatment of congenital NDI is comparable to that of primary NDI. 
[H2] Management of hypernatraemic dehydration 
Most emergency protocols for any patient with hypernatraemic dehydration 
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suggest initial treatment with 0.9% saline, owing to concerns about lowering 
plasma sodium levels too rapidly. The situation differs, however, in patients with 
NDI because of the ongoing losses of essentially pure water with the urine; 
infusion of 0.9% saline will result in excess sodium chloride administration and 
thus worsen the hypernatraemia. In these patients, isotonic fluids should be 
reserved only for acute intravascular volume expansion in hypovolaemic shock, 
which is an exceedingly rare complication, as extracellular fluid volume is 
usually sufficiently preserved in hypernatraemia. Thus, patients with NDI should 
be treated with hypotonic fluids, either enterally (using water or milk) or if 
necessary intravenously (using 5% dextrose in water). Hypotonic fluids must 
never be administered as an intravenous bolus; instead, the infusion rate should 
only slightly exceed the urine output. The aim is to provide just enough water to 
safely normalize plasma sodium concentration at a rate of <0.5 mmol/l per h 
(<10–12 mmol/l per day ). The main risk of a rapid decrease in plasma sodium is 
cerebral oedema and potentially death.94-97 Consequently, careful fluid balance 
and frequent monitoring of clinical state and biochemistries is key to safe 
treatment and requires a clinical environment with sufficient experience in the 
treatment of complicated electrolyte disorders. Fluids should be taken orally as 
soon as feasible, to enable the thirst physiology to properly regulate fluid intake. 
As dextrose in water provides no osmotic load (Box 1), urine output can 
decrease substantially, highlighting the importance of ongoing monitoring and 
fluid balance to avoid rapid swings in plasma sodium concentrations. 
[H2] Diet 
Dieticians have a key role in the management of patients with NDI, especially in 
the first year of life when intake of fluid and calories is coupled. Minimizing the 
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osmotic load (Box 1), whilst providing the recommended caloric and protein 
intake to enable normal growth and development is a cornerstone of paediatric 
NDI management. 
[H2] Thiazide diuretics 
The use of diuretics in polyuric disorders seems counterintuitive. The 
therapeutic potential of these agents in NDI was discovered more or less 
serendipitously, but reported in patients as early as 1905.98 This observation 
was confirmed in the 1950s when administration of hydrochlorothiazide was 
shown to reduce urine output in experimental animals with diabetes insipidus 
by as much as 50%.99 An early study in patients with NDI showed a small 
reduction in urine volume with concomitant increases in urine osmolality and 
sodium shortly after commencing hydrochlorothiazide treatment.100 After 3 days 
of treatment, sodium excretion had decreased to less than baseline, whereas 
urine output had decreased to ~50% of baseline. These changes were associated 
with reductions in plasma volume and body weight. The researchers astutely 
concluded that the initial increase in urine osmolality was related to inhibition of 
urinary dilution, mediated by decreased salt reabsorption through the thiazide-
sensitive co-transporter SLC12A3 in the distal tubule, and that the loss of sodium 
led to a reduction in plasma volume with subsequent enhanced proximal 
reabsorption of the glomerular filtrate, so that less water was presented to the 
collecting duct and lost in the urine. 
 
A SLC12A3-independent mechanism of thiazide-mediated reductions in urine 
output was proposed based on studies in Slc12a3 knock-out mice with lithium-
induced NDI.101 A marked reduction in urine volume with unchanged urine 
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osmolality was observed in these mice after hydrochlorothiazide administration. 
The researchers speculated that this reduction might be mediated by inhibition 
of carbonic anhydrase in the proximal tubule, resulting in reduced proximal 
sodium uptake and consequently—via tubuloglomerular feedback—to 
decreased glomerular filtration. They also found that in mpkCCD cells treated 
with lithium, hydrochlorothiazide administration led to an increase in Aqp2 
abundance at the apical membrane.101 However, the finding that lithium-treated 
and control SLC12A3 knock-out mice had similar urine osmolality after 
hydrochlorothiazide administration suggests that this effect is negligible in vivo. 
 
The hypothesis of impaired proximal sodium reabsorption as a mechanism for 
reduced urine volume in NDI101 is surprising and in direct contrast to the earlier 
hypothesis that enhanced proximal sodium uptake leads to enhanced proximal 
water reabsorption.100 To what degree these apparently opposing mechanisms 
occur in patients remains to be determined. 
[H2] Prostaglandin synthesis inhibitors 
An effect of prostaglandins on epithelial water permeability was noted soon after 
their discovery.102 With the advent of inhibitors of prostaglandin synthesis, such 
as indomethacin, experiments showed a synergistic effect of these new drugs 
with AVP.103 An early study in an animal model of diabetes insipidus 
demonstrated that indomethacin reduced water diuresis independent of AVP.104 
A similar effect of prostaglandin synthesis inhibitors was noted in patients with 
NDI.105-108 
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Prostaglandin synthesis inhibitors have become essential components in the 
treatment of NDI, particularly in the first years of life when management is the 
most complicated. The effect of these drugs can be quite marked when first 
initiated. Indeed, hyponatraemic seizures associated with rapid lowering of 
plasma sodium levels as a result of commencement of indomethacin and 
hydrochlorothiazide have been reported.109 In our experience, urine osmolality 
is unchanged after indomethacin treatment, suggesting that the drug acts mainly 
by enhancing the proximal reabsorption of salt and water.110 
[H1] Future outlook 
[H2] Gene discovery 
Since the discovery of the two known NDI disease genes, AVPR2 and AQP2, in the 
1990s (Figure 4) no additional causative genes have been reported. Mutations in 
AVPR2 or AQP2 are not, however, found in all patients. Between 2003 and 2013, 
the Montreal laboratory performed genetic testing for NDI in 208 families and 
identified causative mutations in AQP2 in 18 families and in AVPR2 in 119 
families (D. Bichet unpublished data). In some of the samples, mutations in genes 
causing renal disorders with secondary forms of NDI, such as Bartter syndrome 
were found, whereas in others, the phenotype was not detailed enough to clearly 
establish a diagnosis of NDI.56 In a Japanese study no mutations were identified 
in 7 of 62 (11%) families with clinical NDI,34 suggesting that genes other than 
AQP2 and AVPR2 might be involved. However the phenotypes of these patients 
were poorly described and not further investigated by the referring physicians.  
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In our clinical experience very few patients with a convincing NDI phenotype 
have no identified mutation. In our Great Ormond Street cohort, we have 
identified three such patients from two families (unpublished data). The results 
of our linkage analyses in these families were, however, consistent with the 
presence of mutations in AVPR2 or AQP2. Thus, if additional NDI disease genes 
are identified, they are likely to be causative only in a small subset of patients. 
[H2] Novel treatments 
The promise of molecular medicine is that through improved understanding of 
specific molecular defects in individual patients, we can develop targeted, 
rational treatments.111 Unfortunately, progress has been slow at best. Although 
several novel treatment approaches for patients with congenital NDI have been 
suggested, little clinical data are available. These novel approaches focus on 
restoring AVP signalling upstream of AQP2 so are not applicable to patients with 
AQP2 mutations.  
[H3] AVPR2 antagonists 
A new treatment strategy for NDI focuses on the fact that most patients carry 
missense mutations in AVPR2 that result in misfolding of AVPR2 and its 
retention in the ER.47 If proper folding is induced using a molecular chaperone, 
the mutant receptor can escape the ER, traffic to the cell membrane and provide 
normal AVP signalling. 
 
Cell-permeable AVPR2 antagonists are molecular chaperones that fit into the 
AVP binding pocket of AVPR2 and induce proper folding of the receptor. In 
patients with suitable mutations, these antagonists might provide a new 
treatment approach for NDI. The problem with this strategy is that the tighter 
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the AVPR2 antagonists fit into the binding pocket, the better they promote 
surface expression of the receptor, but the less likely they are to diffuse off the 
receptor and enable normal AVP signalling. Conversely, compounds with low 
affinity for AVPR2 are less efficient at promoting surface expression, but are 
more likely to diffuse off the receptors that traffic to the cell surface. Antagonists 
with intermediate affinity have the best overall efficacy, but one such agent, the 
orally active, nonpeptide AVPR1A antagonist SR49059, only moderately reduced 
urine volume in five patients with X-linked NDI.112 SR49059 is no longer 
provided by the pharmaceutical company because of the possibility of 
idiosyncratic increases in liver enzymes (these increases were not observed in 
patients with NDI who received the drug) and no further clinical data on this 
treatment approach have been published. 
[H3] AVPR2 agonists 
Cell-permeable agonists that stimulate AVPR2 independent of AVP are another 
potential treatment approach for patients with NDI. As these agents do not block 
AVPR2 signalling they could potentially be a more effective treatment approach 
than AVPR2 antagonists.  
[H3] Vasopressin analogues 
A mutation-specific treatment strategy has also been suggested for patients with 
the Asn321Lys mutation in AVPR2.113 The mutant receptor seems to have normal 
cell surface expression in vitro, but severely decreased affinity for vasopressin 
and DDAVP. AVP signalling via this receptor could reportedly be rescued using 
the vasopressin analogue Val4-desmopressin. Clinical data on the use of this 
compound in patients with NDI bearing this mutation have not yet been 
reported. 
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[H3] Prostaglandin receptor agonists 
 
Another novel treatment approach for patients with AVPR2 mutations focuses on 
enhancing cAMP production in the principal cells independent of AVPR2, for 
example via stimulation of prostaglandin E2 receptors coupled to adenylyl 
cyclase (Figure 3). Such a strategy would not benefit patients with the autosomal 
form of NDI, as AQP2 mutations result in a defect downstream of cAMP 
production. 
 
In a mouse model of X-linked diabetes insipidus with conditional deletion of the 
Avpr2 gene, administration of a prostaglandin E2 receptor EP4 subtype (EP4 
receptor) agonist resulted in an increase in urine concentration.114 The peak 
increase in urine concentration (from 150 mOsm/kg to a maximum of 
500 mOsm/kg) was short lived (3 h), possibly due to down regulation of EP4 
receptors in response to the high osmolality, but with mini-pump constant 
infusions a sustained increase in urine osmolality from 200 mOsmol/kg to 
300 mOsmol/kg was observed. 
 
Doubling of urine osmolality in patients with NDI would halve urine output (to 
~6 l daily in adults) so would constitute successful treatment. In a rat model of 
NDI secondary to the administration of the AVPR2 antagonist, butaprost, an EP2 
receptor agonist approximately doubled urine osmolality.115 To date, no clinical 
data on the use of prostaglandin receptor agonists in patients with NDI have 
been reported. Moreover, given the proven efficacy of prostaglandin synthesis 
inhibitors in NDI treatment, doubts remain as to whether this approach would be 
a viable treatment option.116 
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[H3] Secretin receptor agonists 
The secretin receptor is a G-protein coupled receptor expressed in principal 
cells. Stimulation of this receptor can increase cAMP levels.117 Infusion of 
secretin and fluvastatin resulted in doubling in urine osmolality in mice with 
conditional deletion of the Avpr2 gene.118 If appropriate scientific and ethical 
permission was obtained, short-term therapy with a combination of secretin and 
fluvastatin could potentially be tested in humans with X-linked NDI. Long-term 
secretin treatment might be limited by adverse effects of the drug.  
[H3] cGMP phosphodiesterase inhibitors 
Increased levels of cyclic guanosine monophosphate (cGMP) have been shown to 
enhance trafficking of AQP2 to the luminal membrane and induce a short-lived 
increase in urine osmolality in Brattleboro rats (a model of cerebral diabetes 
insipidus with deficient vasopressin production by the hypothalamus).119 This 
finding suggests a potential role of cGMP phosphodiesterase inhibitors, such as 
sildenafil, in the treatment of patients with NDI resulting from AVPR2 mutations. 
[H3] Gene therapy 
Genome editing of somatic tissue or embryos is of considerable recent interest to 
correct defective genes in humans but the ethics, especially of embryo editing is 
controversial 120  121.. Currently, no such endeavours have reached the clinical 
arena. We anticipate that the ethical governance, safety and long term effects of 
such editing therapies will be determined possibly within the next two decades 
so that patients with hereditary disorders, such as NDI will benefit from them. 
 [H1] Conclusions 
Our understanding of the molecular physiology of urine concentration has 
advanced tremendously in the past 25 years. The study of patients with inherited 
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NDI has identified AVPR2 and AQP2 as key proteins required for the regulation 
of water permeability in the collecting duct. Other tubular disorders, such as 
Bartter syndrome, can present with a secondary form of NDI, which might cause 
diagnostic confusion. In adult nephrology practice, the majority of patients with 
NDI have an acquired form of the disease owing to lithium treatment. Current 
treatment of congenital NDI focuses on dietary modification, thiazides and 
prostaglandin synthesis inhibitors. Novel therapies, such as mutation-specific 
treatment using molecular chaperones, have been investigated in animal models, 
but few data from clinical studies are currently available. The aim of these 
treatment approaches is amelioration of the clinical phenotype of NDI. In the 
future, gene therapy approaches involving kidney-specific delivery of wild-type 
AVPR2 or AQP2 could potentially enable long-term cure of congenital NDI.  
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Box 1: Osmotic load 
The osmotic load consists of osmotically active substances that need to be 
excreted in the urine. The key contributors to the osmotic load are proteins, 
which are metabolized to urea (approximately 4 mmol per g of protein) and 
salts. A typical western diet contains about 800 m0sm per day. An individual 
with a urine osmolality of 800 m0sm/kg only needs 1 l of water to excrete this 
osmotic load, whereas a patient with maximal urine osmolality of 100 m0sm/kg 
will need at least 8 l of water for excretion. 1 g of table salt providing an osmolar 
load of ~36 mOsm (18 mOsm Na and 18 mOsm Cl). Consequently, in a patient 
with a urine osmolality of 100 mOsm/kg, each gram of salt ingested will increase 
the obligatory urine output by 360 ml. The osmolar load of a diet can be roughly 
estimated by multiplying the millimolar amounts of sodium and potassium by 
two (to account for the accompanying anions) and adding the amount of protein 
in g multiplied by four.122 As metabolism of lipids and sugars does not produce 
byproducts that require renal excretion, they do not contribute to the osmotic 
load. Diet is the key contributor to the osmotic load, but metabolism of own 
proteins during catabolic states also generate urea. 
 
Figure 1: The renal concentration and dilution mechanism. The loop of 
Henle forms a counter-current multiplier system that concentrates the urine. 
Urine is isotonic when it enters the loop of Henle and hypotonic when it exits 
into the collecting duct. The concentration gradient generated in the loop of 
Henle is driven by the active reabsorption of NaCl in the thick ascending limb by 
the transporter solute carrier family 12 member 1. The mechanism of 
concentration in the thin descending limb is not completely resolved, but likely 
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involves passive water efflux and/or NaCl influx. Final concentration of urine 
occurs in the collecting duct and depends on the availability of aquaporin 2 
water channels. The approximate osmolalities of the tubular fluid (pink boxes) 
and interstitial fluid (green boxes) are indicated. 
 
Figure 2: Regulation of vasopressin secretion. a | The concentration of various 
ions in the blood is continuously monitored by sensory neurons located in brain 
regions such as the subfornical organ, median preoptic nucleus and organum 
vasculosum lamina terminus.123 These sensory neurons track osmotic conditions and 
signal any perturbations to magnocellular neurosecretory cells in the supraoptic 
nuclei and paraventricular nuclei in the hypothalamus. The magnocellular 
neurosecretory cells then go on to produce and release vasopressin into the 
circulation through the posterior pituitary. The autonomic nervous system also 
regulates kidney function. b | Cell autonomous osmoreception in vasopressin 
neurons. Changes in osmolality cause inversely proportional changes in soma 
volume. Shrinkage activates TRPV1 channels and the ensuing depolarization 
increases action potential firing rate and vasopressin release from axon terminals in 
the neurohypophysis. Increased vasopressin levels in blood enhance water 
reabsorption by the kidney (antidiuresis) to restore extracellular fluid osmolality 
toward the set point. Hypotonic stimuli inhibit TRPV1. The resulting 
hyperpolarization and inhibition of firing reduces vasopressin release and promotes 
diuresis. Abbreviation: TRPV1, transient receptor vanilloid-type 1. Part a modified 
with permission from Nature Publishing Group © Colwell, C. S. Preventing 
dehydration during sleep. Nat. Neurosci. 13, 403–404 (2010). Part b modified with 
permission from John Wiley & Sons Ltd © Prager-Khoutorsky, M. & Bourque, C. W. 
Mechanical basis of osmosensory transduction in magnocellular neurosecretory 
neurons of the rat supraoptic nucleus. J. Neuroendocrinol. 
http://dx.doi.org/10.1111/jne.12270. 
 
Figure 3: Water transport in the principal cell. Binding of AVP to the AVPR2 
receptor expressed on the basolateral side of the principal cell stimulates the 
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release of GαS, which in turn activates adenylyl cylase, resulting in increased 
cAMP production. PKA is activated by cAMP and phosphorylates several residues 
in the C-terminus of AQP2. This phosphorylation enables trafficking of AQP2 to 
the apical membrane and the formation of AQP2 water channels. AQP2 is 
constantly retrieved from the membrane by endocytosis, so that ongoing water 
permeability depends on delivery of AQP2 to the membrane, either by recycling 
or generation of new channels. Water diffuses via these channels along the 
concentration gradient from the tubular lumen into the principal cell and exits 
into the interstitium via the constitutively expressed AQP3 and AQP4 water 
channels. In addition to PKA-mediated phosphorylation ofAQP2, cAMP enhances 
transcription of AQP2. Some of the changes induced by cAMP are likely mediated 
by EPAC. The G-protein coupled receptors EP2, EP4 and the secretin receptor are 
also expressed in principal cells. Targeting of these receptors could potentially 
be used to stimulate membrane insertion of AQP2 in the absence of functional 
AVPR2. Abbreviations: AQP, aquaporin; AVP, arginine vasopressin; AVPR2, 
vasopressin V2 receptor; CREB, cAMP responsive element binding protein; EP2, 
prostaglandin E2 receptor EP2 subtype; EP4, prostaglandin E2 receptor EP4 
subtype; EPAC, exchange protein directly activated by cAMP; G, G protein; PKA, 
protein kinase A. 
 
Figure 4 | Timeline of key advances in the understanding of nephrogenic 
diabetes insipidus. Abbreviations: AQP2, aquaporin 2; AVP, arginine 
vasopressin; AVPR2, vasopressin V2 receptor. 
